Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Priority claimed from PCT/US2014/021130external-prioritypatent/WO2014138368A1/en
Publication of MA38451A1publicationCriticalpatent/MA38451A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
L'invention concerne des benzoimidazol-2-ylpyrimidines, leurs procédés de purification, des compositions pharmaceutiques et des méthodes de traitement d'états pathologiques, de troubles et de maladies médiés par l'activité du récepteur de hThe invention relates to benzoimidazol-2-ylpyrimidines, methods for their purification, pharmaceutical compositions and methods for treating disease states, disorders and diseases mediated by h receptor activity.
MA38451A2013-03-062014-03-06
Benzoimidazol-2-ylpyrimidines modulating the histamine h4 receptor
MA38451A1
(en)
3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES